

Modeling formalisms and Small models of inflammation

Gilles Clermont

Medical Director, Center for Inflammation and Regenerative modeling Department of Critical Care Medicine, University of Pittsburgh



Objectives

What is a model.
Modeling formalisms
Specific models
Population variability



What is a model

 $Y(state) \xrightarrow{Model} X(observations)$

- Simplified representation of a complicated reality (the system)
- Captures (describes) key behaviors of reality
- Two basic choices:
 - Level of system specification
 - Pathways vs Cells vs Organs vs Organism
 - Multiscale
 - Modeling framework specification
 - Mathematical/statistical/others



Why a model?

Predictions Survival Hurricane path and strength Insight/interpretation What-if scenarios? "Rank" drivers of outcome



Model structure Variables and Parameters

Y = mX + b

• Variables (Y, X) are:

- Input into the model, output from the model (state)
- Independent predictors
- Observable from the system
- Parameters (m, b) are:
 - Integral part of the specification of the model
 - Adjusted to have model "fit" the data
 - Poor fit suggest the model does not capture the behavior of the system



Scale and granularity





Statistical (data-driven) models

 What they can do Classify Discriminate (ROC) Cluster Predict (calibration, e.g. R²) What form do they take Regression Machine learning Neural networks Graphical Many others Combinations



Time-dependent statistical predictions





Actual vs predicted





Statistical models

Advantages

- Good to predict population outcome
- Take advantage of associations
- Disadvantages
 - Not as good to predict the outcome of an individual, except at extreme of predictions
 - Knowledge poor, no inclusion of a priori known mechanisms
 - Require large amount of data
 - Subject to assumptions (e.g. distribution of data) that may not always be fulfilled
 - Require careful approach to missing data



Equation-based models

- Non-dynamical Describes relationships between variables Typically algebraic Description of steady-states, transients unimportant Most traditional physiologic model Cardiopulmonary physiology Dynamical Difference equations Differential equations Time-dependence (Ordinary DE)
 - Time and space-dependence (Partial DE)



Equation-based models

- Knowledge-rich
- Basic laws (rules) of the system are provided a priori
 - Also true of agent-based models
- Clear sense of causality
- May or may not be constructed as to reflect physical reality
 - Can be very high level
- Although basically deterministic, can clearly accommodate stochastic elements, thus uncertain knowledge
- Well developed mathematical theory



Scale and granularity





Equation-based models - caveats

- Even small systems can have large number of parameters
 - Parameter reduction techniques are available
- Many of the parameters are not known
 - Even if we think we have good literature documentation
 - Biological data was typically not collected with modeling in mind
 - Molecule half-life
 - Reaction rates
- Models are typically underspecified: many different combination of parameters can explain data equally well
- Structure vs parameters problem
- Underlying assumptions may not be fulfilled (e.g. continuity)



Viral Models – Population based

- Largely empirical
 - Susceptible, Infected, Recovered/resistant
- Yet, knowledge of basic determinant of such models is important
 - R₀, θ
 - Social networks
 - Health delivery services infrastructure



Motivation for biological models

 Explain input to larger models Explain manifestation of disease Disease severity Age, co-morbidity Explore modifiers of disease that act at the individual level Susceptibility Transmissibility Vaccine effect Antibiotics



Population models





Biological models

Models of Host-Virus interaction
HIV (a lot), as well as other retroviruses
Influenza, HBV, West Nile, Smallpox
Little traction in translational research
Exception is multiple interruptions of therapy in HIV carriers

55

Biological Models of viral infections

- Since early 1990's
- HIV
 - Nowak, Perelson, Kirschner, Wodarz
 - Object
 - HIV/CD4+ interaction
 - Optimizing therapy
 - Dynamics of viral mutation and multiple infections
- Influenza
 - Bocharov, Hancioglu, Beauchemin
- Hepatitis B, C
 - Bocharov





The "reaction" formulation

λ $* \rightarrow x$ k $y \rightarrow v$ β $v + x \rightarrow y$ d U a $x \rightarrow *, v \rightarrow *, y \rightarrow *$ X: healthy cell Y: infected cell V: virus R: killer cell

$$\begin{aligned} \mathbf{x} &= \lambda - \beta v \mathbf{x} - d \mathbf{x} \\ \mathbf{y} &= \beta v \mathbf{x} - a \mathbf{y} \\ \mathbf{y} &= k \mathbf{y} - u \mathbf{v} - \beta v \mathbf{x} \end{aligned}$$



With a killer cell (r)



$$\begin{aligned} x &= \lambda - \beta v x - d x \\ y &= \beta v x - a y \\ v &= k y - u v - \beta v x \end{aligned}$$

$$y + r \rightarrow r$$

$$c \qquad f$$

$$r \rightarrow r$$

$$\mathbf{\dot{y}} = \beta vx - ay - \gamma ry$$

$$\mathbf{\dot{r}} = c - fr$$

The reverse transcriptase example





A (slightly) more realistic model

HIV infects CD4+ cells

- These CD4+ cells are responsible for the clonal expansion of cytotoxic T lymphocytes
- Could "controlling" virus expression allow sufficient CD4+ activation to allow sufficient CTL to maintain a chronic carrier state – given a fixed antigenic mutation rate?



Lessons learned from biological models of HIV

- Rapid drift, a major impediment for vaccine development, is our worse enemy preserved ability of clonal development of CTLs
- Models have predicted that an optimal strategy for HIV containment would include:
 - Early HAART (highly active anti retroviral therapy) intervention
 - Frequent interruptions of therapy to minimize drift while CTL clones are enrolled (Structure Treatment Interruption, DRUGS 2002)



Translation (STI strategy)

SMART, OPTIMA (in unsuppressed HIV)

Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults (Review)

Pai NP, Tulsky JP, Lawrence J, Colford Jr JM, Reingold AL

• STACCATO (Lancet 8/2006)

CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial

Jintanat Ananworanich, Angèle Gayet-Ageron, Michelle Le Braz, Wisit Prasithsirikul, Ploenchan Chetchotisakd, Sasisopin Kiertiburanakul, Warangkana Munsakul, Phitsanu Raksakulkarn, Somboon Tansuphasawasdikul, Sunee Sirivichayakul, Matthias Cavassini, Urs Karrer, Daniel Genné, Reto Nüesch, Pietro Vernazza, Enos Bernasconi, Dominic Leduc, Claudette Satchell, Sabine Yerly, Luc Perrin, Andrew Hill, Thomas Perneger, Praphan Phanuphak, Hansjakob Furrer, David Cooper, Kiat Ruxrungtham, Bernard Hirschel, the Staccato Study Group*, the Swiss HIV Cohort Study*



Inflammation – a reduced model



Anti-inflammation



Inflammation – a reduced model





The reaction system

р	\rightarrow	2 p	
р	+ <i>p</i>	\rightarrow	p
p	+ <i>m</i>	\rightarrow	т
т	+ p	\rightarrow	2 m
т	+ <i>m</i>	\rightarrow	т
$m \rightarrow *$			
т	\rightarrow	<i>m</i> +	l
$l \rightarrow *$			

The DE formulation

$$\frac{dp}{dt} = k_p p (1-p) - k_{pm} m p \tag{1}$$

$$\frac{dm}{dt} = (k_{mp} p + l) m (1-m) - m \tag{2}$$

$$\frac{dl}{dt} = k_{lm} f(m) - k_l l \tag{3}$$

$$f(m) = 1 + \tanh\left(\frac{m-\theta}{w}\right), \tag{4}$$

p is pathogen, *m* is a pathogen predator, *I* is a late mediator, possibly tissue dysfunction. So, 3 variables, 7 parameters.

Kumar et al. J Theoretical Biol 2004



Possible "steady-state" behaviors

$$\mathbf{0} = k_p p (1-p) - k_{pm} m p \tag{1}$$

$$\mathbf{0} = (k_{mp}p + l)m(1 - m) - m \tag{2}$$

$$\mathbf{D} = k_{lm} f(m) - k_l l \tag{3}$$

Up to five solutions = fixed points or orbits

- A solution is a combination of *p*, *m* and *l* that fulfills all equations simultaneously
- Each solution depends on the actual parameter values



What are possible outcomes?

FP3

FP5

Sterile death



FP2 Immune failure death















The notion of stable/unstable regimen





The need for a "late mediator"





Insights from a simple model

- Only 3 (4) regimen are ever possible
 Cure
 - Oscillations with low grade pathogens
 - Aseptic death
 - Immunesuppression (septic death)
- There are specific conditions for the existence of those regimen
- There cannot be "aseptic" death if collateral damage production does not exceed a certain threshold



Anti-inflammation (ca)



Manipulating anti-inflammatories





Why complicate things

- To calibrate a model, we need to confront it to data
- To "intervene" in the dynamics in a realistic way, more realistic "handles" are needed
- Variability
- Not all "modules" need to be equally complicated
- The analysis of large models:
 - May rapidly become intractable
 - May not yield useful results



Multiscale models - the lung

- Oxygen and carbon dioxide exchange
- Inflammation occurs in the tissue barrier between air and blood.
- Tissue swelling impairs gas diffusion. Extreme inflammation of a respiratory unit (~25 alveoli) can completely stop gas exchange (shunt).
- The global impact of inflammation depends on the combined contribution of respiratory units (RU) with diverse anatomical and physiologic properties.



Model schematics



Simulation results Gas exchange – single unit





Simulation results Lung volumes – single unit

Non-Lethal



Lethal





Full lung model Assembling heterogeneous units





Simulation - Full lung model



33

Optimization

Parameter identification Inverse problem / data assimilation Variability Control Modify inputs to a model to achieve a desired outcome



$E(M_n) \equiv$ Metamodel or Ensemble

Where the individual models vary in their mathematical structure and parameters



Population variability in the response to Influenza virus

- Uncertainty in available data: measurement error
- Inter-individual variations

Best approached with stochastic methods





Variability in the normal response





Recurrence of disease...





...and Superspreaders





Conclusions

- Inflammation has several different components
- Inflammation is a multiscale problem
- A variety of modeling formalisms can be used